Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06028711
Other study ID # URzeszow/2023/06/0034/W
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 2023
Est. completion date December 2024

Study information

Verified date August 2023
Source University of Rzeszow
Contact Renata Borys, MSc
Phone +48 784 016 220
Email rborys@ur.edu.pl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The planned research will enable the assessment of rehabilitation's effects using two pulmonary rehabilitation models: conventional and supplemented with an education program for patients hospitalized due to chronic obstructive pulmonary disease.


Description:

The planned group size is 100 patients diagnosed with chronic obstructive pulmonary disease (COPD) and hospitalized due to exacerbation. The given population was calculated based on the sampling calculator, considering the following parameters: fraction size, confidence level, and maximum error. Eligible patients will be randomly divided into two groups: a study group (50 patients) undergoing pulmonary rehabilitation supplemented with an education program and a control group (50 patients) undergoing conventional pulmonary rehabilitation. Patients of both groups will be included in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient, including active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles, and cardiopulmonary exercises. Patients from the study group will additionally undergo daily education using an original brochure containing information on the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise, and risk factors for exacerbation of COPD. The test will be performed three times: before the start of rehabilitation, after completing the rehabilitation program, and the follow-up after two months from the end of hospitalization to assess long-term effects. After the end of the study, people from the control group will also undergo education. The patients' condition and the rehabilitation effects will be assessed using the following measures: - Dynamic lung capacities (spirometry) - Oxygen saturation and pulse rate (pulse oximeter) - Acid-base balance (gasometry) - Exercise tolerance (6-minute walking test) - Fatigue (modified Borg scale) - Physical performance (Fullerton functional fitness test) - Dyspnea assessment (MRC dyspnea scale) - Quality of life (WHOQOL-BREF) - Anxiety and depression (HADS scale) - Activities of daily living (Lawton IADL scale)


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date December 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 55 Years to 70 Years
Eligibility Inclusion Criteria: - Diagnosed chronic obstructive pulmonary disease in the exacerbation phase - Moderate stage (II) of the disease - Independence in basic activities of daily living (above 86 points on the Barthel scale) - Age 55 y.o. to 70 y.o. - No additional respiratory support (e.a. cardiopulmonary bypass machine, ventilator) - Informed, voluntary consent to participate in research. Exclusion Criteria: - Diagnosed chronic obstructive pulmonary disease in remission - Stages I, III and IV of the disease - a forms with mild, severe, and very severe obstruction - Hospitalization in the intensive care unit, current health condition precluding participation in the study - Age under 55 y.o. and over 70 y.o. - Cognitive deficits impairing the ability to understand and execute commands - Concomitant oncological, neurological, orthopedic, and psychiatric diseases may affect the examined persons' circulatory and respiratory functions, functional efficiency, quality of life, and emotional state. - Failure to complete a 14-day rehabilitation program - Lack of informed, voluntary consent to participate in research.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Education program
Patients in a study group will participate in daily education program using an original brochure containing information on the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise, and risk factors for exacerbation of COPD.
Pulmonary rehabilitation
The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient and include active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.

Locations

Country Name City State
Poland University of Rzeszów Rzeszów

Sponsors (1)

Lead Sponsor Collaborator
University of Rzeszow

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dynamic lung capacities (spirometry) Measurements will be performed with certified spirometer and the parameters analyzed will be Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 Second (FEV1) measured in litres [L]. First examination- before the start of the interventions
Primary Dynamic lung capacities (spirometry) Measurements will be performed with certified spirometer and the parameters analyzed will be Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 Second (FEV1) measured in litres [L]. Second examination- at the end of the 14-day rehabilitation program
Primary Modified Tiffeneau-Pinelli index (spirometry) Measurement will be performed with certified spirometer and the parameter analyzed will be the ratio of Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC ratio) presented as a decimal fraction. First examination- before the start of the interventions
Primary Modified Tiffeneau-Pinelli index (spirometry) Measurement will be performed with certified spirometer and the parameter analyzed will be the ratio of Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC ratio) presented as a decimal fraction. Second examination- at the end of the 14-day rehabilitation program
Primary Oxygen saturation Measurements will be performed with pulse oximeter and the parameter analyzed will be oxygen saturation by pulse oximetry (SpO2, percentage of oxygen in patients' blood). First examination- before the start of the interventions
Primary Oxygen saturation Measurements will be performed with pulse oximeter and the parameter analyzed will be oxygen saturation by pulse oximetry (SpO2, percentage of oxygen in patients' blood). Second examination- at the end of the 14-day rehabilitation program
Primary Pulse rate Measurements will be performed with pulse oximeter and the parameter analyzed will be the number of patients' heart beats per minute. First examination- before the start of the interventions
Primary Pulse rate Measurements will be performed with pulse oximeter and the parameter analyzed will be the number of patients' heart beats per minute. Second examination- at the end of the 14-day rehabilitation program
Primary Acid-base balance The gasometry results will be taken from patients' medical documentation. The parameters analyzed will be oxygen pressure (pO2) and carbon dioxide pressure (pCO2). First examination- before the start of the interventions
Primary Acid-base balance The gasometry results will be taken from patients' medical documentation. The parameters analyzed will be oxygen pressure (pO2) and carbon dioxide pressure (pCO2). Second examination- at the end of the 14-day rehabilitation program
Primary Exercise tolerance assessed by 6-minute walking test (6MWT) The test will be performed in 20-meter long hospital corridor. The patient should walk the distance at his own rhythm and pace, using orthopedic aids (if necessary). The patient will be informed that they can stop the test at any time if they feel it is necessary. The distance traveled in meters in 6 minutes will be analyzed. First examination- before the start of the interventions
Primary Exercise tolerance assessed by 6-minute walking test (6MWT) The test will be performed in 20-meter long hospital corridor. The patient should walk the distance at his own rhythm and pace, using orthopedic aids (if necessary). The patient will be informed that they can stop the test at any time if they feel it is necessary. The distance traveled in meters in 6 minutes will be analyzed. Second examination- at the end of the 14-day rehabilitation program
Primary Physical performance assessment by Fullerton functional fitness test The test comprising muscle endurance, aerobic capacity, flexibility, agility, and balance assessment. The test consist of 6 activities: 1. Arm Curl Test (number of forearm flexions in 30 seconds); 2. Back Scratch (the distance between middle fingers); 3. 30 Second Chair Stand (number of standings in 30 seconds); 4. Chair Sit-and-Reach ( '+' if fingers can reach toes in sitting position, '-' if fingers cannot reach toes in sitting position); 5. 8 - Foot Up-and-Go (8-foot walking time); 6. 2-Minute Step-in-Place (the number of lifts of the right leg). First examination- before the start of the interventions
Primary Physical performance assessment by Fullerton functional fitness test The test comprising muscle endurance, aerobic capacity, flexibility, agility, and balance assessment. The test consist of 6 activities: 1. Arm Curl Test (number of forearm flexions in 30 seconds); 2. Back Scratch (the distance between middle fingers); 3. 30 Second Chair Stand (number of standings in 30 seconds); 4. Chair Sit-and-Reach ( '+' if fingers can reach toes in sitting position, '-' if fingers cannot reach toes in sitting position); 5. 8 - Foot Up-and-Go (8-foot walking time); 6. 2-Minute Step-in-Place (the number of lifts of the right leg). Second examination- at the end of the 14-day rehabilitation program
Primary Fatigue assessment using modified Borg scale Fatigue will be examined during physical activity and the level of fatigue will be marked on a scale from 1 (no fatigue) to 10 (very very hard fatigue). First examination- before the start of the interventions
Primary Fatigue assessment using modified Borg scale Fatigue will be examined during physical activity and the level of fatigue will be marked on a scale from 1 (no fatigue) to 10 (very very hard fatigue). Second examination- at the end of the 14-day rehabilitation program
Primary Fatigue assessment using modified Borg scale Fatigue will be examined during physical activity and the level of fatigue will be marked on a scale from 1 (no fatigue) to 10 (very very hard fatigue). Third examination - two months after discharge from the hospital (follow- up)
Primary Dyspnea assessment with Medical Research Council dyspnea scale Perceived breathlessness degree will be marked on a scale 0 (no breathlessness) to 4 (breathlessness at rest). First examination- before the start of the interventions
Primary Dyspnea assessment with Medical Research Council dyspnea scale Perceived breathlessness degree will be marked on a scale 0 (no breathlessness) to 4 (breathlessness at rest). Second examination- at the end of the 14-day rehabilitation program
Primary Dyspnea assessment with Medical Research Council dyspnea scale Perceived breathlessness degree will be marked on a scale 0 (no breathlessness) to 4 (breathlessness at rest). Third examination - two months after discharge from the hospital (follow- up)
Primary Quality of life assessment using World Health Organization Quality-of-Life Scale (WHOQOL-BREF) Assessment of quality of life, health and other areas. The scale contains 26 items, divided into four domains: physical health (7 items), psychological health (6 items), social relations (3 items), and environmental health (8 items), as well overall quality of life and general health (2 items). Patients express how much they have experienced the items in the preceding 2 weeks on a 5-point Likert scale ranging from 1 (not at all) to 5 (completely). The final score is transformed linearly to a 0-100-scale, where higher scores denote higher quality of life. First examination- before the start of the interventions
Primary Quality of life assessment using World Health Organization Quality-of-Life Scale (WHOQOL-BREF) Assessment of quality of life, health and other areas. The scale contains 26 items, divided into four domains: physical health (7 items), psychological health (6 items), social relations (3 items), and environmental health (8 items), as well overall quality of life and general health (2 items). Patients express how much they have experienced the items in the preceding 2 weeks on a 5-point Likert scale ranging from 1 (not at all) to 5 (completely). The final score is transformed linearly to a 0-100-scale, where higher scores denote higher quality of life. Second examination- at the end of the 14-day rehabilitation program
Primary Quality of life assessment using World Health Organization Quality-of-Life Scale (WHOQOL-BREF) Assessment of quality of life, health and other areas. The scale contains 26 items, divided into four domains: physical health (7 items), psychological health (6 items), social relations (3 items), and environmental health (8 items), as well overall quality of life and general health (2 items). Patients express how much they have experienced the items in the preceding 2 weeks on a 5-point Likert scale ranging from 1 (not at all) to 5 (completely). The final score is transformed linearly to a 0-100-scale, where higher scores denote higher quality of life. Third examination - two months after discharge from the hospital (follow- up)
Primary Anxiety and depression assessment using HADS scale The scale consists of 16 statements to which the respondent refers on a four-point scale. Eight statements are used to measure anxiety and depression, each of which is rated on a scale of 0 to 3 points. The cut-off threshold is 7 points for depression and 7 points for anxiety. The intensity of depressed mood and anxiety will be analyzed. First examination- before the start of the interventions
Primary Anxiety and depression assessment using HADS scale The scale consists of 16 statements to which the respondent refers on a four-point scale. Eight statements are used to measure anxiety and depression, each of which is rated on a scale of 0 to 3 points. The cut-off threshold is 7 points for depression and 7 points for anxiety. The intensity of depressed mood and anxiety will be analyzed. Second examination- at the end of the 14-day rehabilitation program
Primary Anxiety and depression assessment using HADS scale The scale consists of 16 statements to which the respondent refers on a four-point scale. Eight statements are used to measure anxiety and depression, each of which is rated on a scale of 0 to 3 points. The cut-off threshold is 7 points for depression and 7 points for anxiety. The intensity of depressed mood and anxiety will be analyzed. Third examination - two months after discharge from the hospital (follow- up)
Primary Activities of daily living assesment using Lawton Instrumental Activities of Daily Living (IADL) Scale Life independence test, i.e. ensuring the functioning of the household by a sick person based on his/her ability to cope in the external environment or with a complex activity such as using the telephone and ensuring the related opportunities. The ability of basic functioning in the environment will be analyzed and each of 8 items will be rate trichotomously (1 = unable, 2 = needs assistance, 3 = independent) and sum the eight responses. The final total score ranges from 8 (low functioning, dependent) to 24 (high function, independent). First examination- before the start of the interventions
Primary Activities of daily living assesment using Lawton Instrumental Activities of Daily Living (IADL) Scale Life independence test, i.e. ensuring the functioning of the household by a sick person based on his/her ability to cope in the external environment or with a complex activity such as using the telephone and ensuring the related opportunities. The ability of basic functioning in the environment will be analyzed and each of 8 items will be rate trichotomously (1 = unable, 2 = needs assistance, 3 = independent) and sum the eight responses. The final total score ranges from 8 (low functioning, dependent) to 24 (high function, independent). Second examination- at the end of the 14-day rehabilitation program
Primary Activities of daily living assesment using Lawton Instrumental Activities of Daily Living (IADL) Scale Life independence test, i.e. ensuring the functioning of the household by a sick person based on his/her ability to cope in the external environment or with a complex activity such as using the telephone and ensuring the related opportunities. The ability of basic functioning in the environment will be analyzed and each of 8 items will be rate trichotomously (1 = unable, 2 = needs assistance, 3 = independent) and sum the eight responses. The final total score ranges from 8 (low functioning, dependent) to 24 (high function, independent). Third examination - two months after discharge from the hospital (follow- up)
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy